These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 25966690)

  • 1. Pharmacology of L-type Calcium Channels: Novel Drugs for Old Targets?
    Striessnig J; Ortner NJ; Pinggera A
    Curr Mol Pharmacol; 2015; 8(2):110-22. PubMed ID: 25966690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L-type calcium channels as drug targets in CNS disorders.
    Ortner NJ; Striessnig J
    Channels (Austin); 2016; 10(1):7-13. PubMed ID: 26039257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular effects of calcium channel antagonists: new evidence.
    Richard S
    Drugs; 2005; 65 Suppl 2():1-10. PubMed ID: 16398057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential.
    Zamponi GW; Striessnig J; Koschak A; Dolphin AC
    Pharmacol Rev; 2015 Oct; 67(4):821-70. PubMed ID: 26362469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs.
    Perez-Reyes E; Van Deusen AL; Vitko I
    J Pharmacol Exp Ther; 2009 Feb; 328(2):621-7. PubMed ID: 18974361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cav1.4alpha1 subunits can form slowly inactivating dihydropyridine-sensitive L-type Ca2+ channels lacking Ca2+-dependent inactivation.
    Koschak A; Reimer D; Walter D; Hoda JC; Heinzle T; Grabner M; Striessnig J
    J Neurosci; 2003 Jul; 23(14):6041-9. PubMed ID: 12853422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of S(+)-efonidipine on the rabbit sinus node action potential and calcium channel subunits Ca(V)1.2, Ca(V)1.3 and Ca(V)3.1.
    Tanaka H; Namekata I; Ogawa T; Tsuneoka Y; Komikado C; Takahara A; Iida-Tanaka N; Izumi-Nakaseko H; Tsuru H; Adachi-Akahane S
    Eur J Pharmacol; 2010 Dec; 649(1-3):263-7. PubMed ID: 20858482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural and functional differences between L-type calcium channels: crucial issues for future selective targeting.
    Zuccotti A; Clementi S; Reinbothe T; Torrente A; Vandael DH; Pirone A
    Trends Pharmacol Sci; 2011 Jun; 32(6):366-75. PubMed ID: 21450352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modest CaV1.342-selective inhibition by compound 8 is β-subunit dependent.
    Huang H; Ng CY; Yu D; Zhai J; Lam Y; Soong TW
    Nat Commun; 2014 Jul; 5():4481. PubMed ID: 25057870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired chromaffin cell excitability and exocytosis in autistic Timothy syndrome TS2-neo mouse rescued by L-type calcium channel blockers.
    Calorio C; Gavello D; Guarina L; Salio C; Sassoè-Pognetto M; Riganti C; Bianchi FT; Hofer NT; Tuluc P; Obermair GJ; Defilippi P; Balzac F; Turco E; Bett GC; Rasmusson RL; Carbone E
    J Physiol; 2019 Mar; 597(6):1705-1733. PubMed ID: 30629744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular pharmacology of high voltage-activated calcium channels.
    Doering CJ; Zamponi GW
    J Bioenerg Biomembr; 2003 Dec; 35(6):491-505. PubMed ID: 15000518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ca2+ channel subtypes and pharmacology in the kidney.
    Hayashi K; Wakino S; Sugano N; Ozawa Y; Homma K; Saruta T
    Circ Res; 2007 Feb; 100(3):342-53. PubMed ID: 17307972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Voltage-dependent calcium channels.
    Lacinová L
    Gen Physiol Biophys; 2005 Jun; 24 Suppl 1():1-78. PubMed ID: 16096350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular basis of drug interaction with L-type Ca2+ channels.
    Mitterdorfer J; Grabner M; Kraus RL; Hering S; Prinz H; Glossmann H; Striessnig J
    J Bioenerg Biomembr; 1998 Aug; 30(4):319-34. PubMed ID: 9758329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical cfficacy of calcium channel blockers slow the third generation of lercanidipine in the treatment of patients with arterial hypertension].
    Maksimov ML; Malykhina AI
    Kardiologiia; 2013; 53(6):85-90. PubMed ID: 23953051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic potential of Voltage gated Calcium channels.
    Mohan CG; Gandhi T
    Mini Rev Med Chem; 2008 Oct; 8(12):1285-90. PubMed ID: 18855741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ascidian dihydropyridine-resistant calcium channel as the prototype of chordate L-type calcium channel.
    Okamura Y; Izumi-Nakaseko H; Nakajo K; Ohtsuka Y; Ebihara T
    Neurosignals; 2003; 12(3):142-58. PubMed ID: 12904687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Competitive and cooperative effects of Bay K8644 on the L-type calcium channel current inhibition by calcium channel antagonists.
    Zahradníková A; Minarovic I; Zahradník I
    J Pharmacol Exp Ther; 2007 Aug; 322(2):638-45. PubMed ID: 17475903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of effects of L/N-type and L-type calcium channel blockers on post-infarct cardiac remodelling in spontaneously hypertensive rats.
    Naseratun N; Kobara M; Watanabe Y; Toba H; Nakata T
    Clin Exp Pharmacol Physiol; 2020 Sep; 47(9):1545-1553. PubMed ID: 32323339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivation of L-type calcium channels is determined by the length of the N terminus of mutant beta(1) subunits.
    Jangsangthong W; Kuzmenkina E; Khan IF; Matthes J; Hullin R; Herzig S
    Pflugers Arch; 2010 Feb; 459(3):399-411. PubMed ID: 19821165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.